BABOON OPSONOKINE VACCINE STUDY

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。在小鼠模型中，一种新的免疫系统刺激剂Opsonokine在诱导针对癌症靶点和传染性疾病靶点（乙型肝炎病毒，HBV）的强免疫细胞反应（杀伤细胞反应）方面显示出很大的希望。调理因子由一种蛋白质组成，通常在体内参与激活和招募参与向免疫系统呈递目标的细胞（即抗原呈递细胞，APC）。这种蛋白，人GMCSF（粒细胞单核细胞集落刺激因子），与流感分子（GM-CSF-HA）有关。转基因csf - ha与唾液酸结合，唾液酸几乎存在于所有哺乳动物细胞中，并允许现在“粘性”的分子结合并停留在注射部位，防止其扩散。我们将使用HBV靶蛋白HBsAg（乙型肝炎表面抗原）与两种不同浓度的调理因子混合来评估HBV疫苗。我们将研究在狒狒中诱导抗hbsag细胞毒性（杀伤）t细胞反应和b细胞抗体反应。这将通过首先在0天和28天对动物进行免疫，并在接下来的14周内收集血液样本以确定免疫反应来完成。现有的乙肝疫苗仅限于保护个人免受感染，但对已经感染的患者不起治疗作用。这里的目标是确定我们是否能产生适当的免疫反应，最终产生一种治疗已经感染了传染病病毒的个体的方法。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A new immune system stimulator, Opsonokine, has shown great promise in inducing strong immune cell responses (killer cell responses) against both cancer targets and infectious disease targets (Hepatitis B Virus , HBV) in mouse models. The Opsonokine consists of a protein normally involved in the body to activate and recruit cells involved in presenting targets to the immune system (so called Antigen Presenting Cells, APC). This protein, human GMCSF (granulocyte monocyte - colony stimulating factor), is linked to the influenza molecule (GM-CSF-HA). The GM-CSF-HA binds to sialic acid, which is present on virtually all mammalian cells and allows the now ¿sticky¿ molecule to bind and stay at the injection site which prevents it from diffusing away. We will evaluate an HBV vaccine, using the HBV target protein HBsAg (Hepatitis B surface antigen) mixed with two different concentrations of the Opsonokine. We will study the induction in the baboon of both an anti-HBsAg cytotoxic (killer) T-cell response and B-cell antibody response. This will be done by first immunizing the animals at 0 and 28 days and for the next 14 weeks collect blood samples to determine the immune response. The existing vaccines for HBV are limited to protecting individuals from infection but do not work as therapy in already infected patients. The goal here is to determine if we can generate a proper immune response that ultimately results in a therapy for individuals already infected with a infectious disease virus.